As the original poster implied, once clinical trials are underway, and say, the A/S have already been brought into play, a healthier share structure might be desired.
At that time, funding for the trials hopefully would not come from further dilution.
Of course, in most other instances, as you state, a R/S is absolutely a very bad sign in pennyland.